TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, ...
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the...
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces that the Irish High Court (the “Court”) has today sanctioned, without modification, the scheme of arrangement between Avadel and its shareholders unde...
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis Campaign debuted during Super Bowl LX and introduced , a new platform designed to create space for honest conversation among people living with MS NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease. Christina Applegate, who has been living with MS for 5 years, will...
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer an...
RGC Resources, Inc. Reports First Quarter 2026 Earnings ROANOKE, Va., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $4.9 million, or $0.47 per share, for the first quarter ended December 31, 2025, compared to $5.3 million, or $0.51 per share, for the first quarter ended December 31, 2024. The decrease reflected flat margins and higher costs for personnel, IT, property taxes and depreciation, which were partially offset by lower interest expense. The Company filed a rate case in early December seeking $4.3 million in additio...
Full House Resorts Announces Fourth Quarter Earnings Release Date LAS VEGAS, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Full House Resorts (NASDAQ: FLL) announced today that it will report its fourth quarter 2026 financial results on Thursday, March 5, 2026, followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the live audio webcast from the Company’s website at under the investor relations section. The conference call can also be accessed by dialing (201) 689-8470. A replay of the conference call will be available shortly after the conclusion of the call through Ma...
Interparfums, Inc. Announces Exclusive Worldwide License Agreement With Nautica NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that it has entered into an exclusive, 20-year worldwide license agreement with global lifestyle brand Nautica for the creation, development, production, and distribution of fragrances under the Nautica brand name. Jean Madar, Chairman and Chief Executive Officer of Interparfums, said, “Nautica is world-renowned for bringing the inspiration of the sea to everyday style. We are thr...
Interparfums, Inc. Announces Exclusive Worldwide License Agreement with David Beckham NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that it has entered into an exclusive, 20-year worldwide license agreement with David Beckham for the creation, development, production, and distribution of fragrances under the David Beckham brand. Jean Madar, Chairman and Chief Executive Officer of Interparfums, said, “We are delighted to collaborate with David Beckham, who embodies modern sophistication and timeless elega...
RGC Resources, Inc. Schedules First Quarter 2026 Earnings Call ROANOKE, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal first quarter 2026 on Tuesday, February 10, 2026 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at . Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An arc...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, California. Abstracts are now available online and can be acc...
RGC Resources Holds Annual Shareholders Meeting ROANOKE, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) announced the election of Directors at its shareholders meeting held on January 26, 2026. Shareholders elected Jacqueline L. Archer, Frank Russell Ellett and Robert B. Johnston for three-year terms. Shareholders also ratified the appointment of Deloitte & Touche, LLP as auditors for fiscal 2026. At a meeting of the Board of Directors, following the annual shareholders meeting, John B. Williamson III was elected Chairman of the Board and Paul W. Nester was el...
Guess?, Inc. and Interparfums, Inc. Extend Their Fragrance Partnership Through 2048 NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced a 15-year extension of its exclusive worldwide license agreement with Guess?, Inc., for the continued creation, development and distribution of its fragrances, extending the agreement length for 23 more years. Jean Madar, Chairman & Chief Executive Officer of Interparfums, said, “This extension underscores the enduring strength of our partnership with Guess?, Inc. After more t...
Interparfums, Inc. Reports Record 2025 Fourth Quarter and Full Year Net Sales Full Year 2025 Net Sales Rose to $1.49 Billion 2025 Fourth Quarter & Full Year Conference Call Scheduled for February 25, 2026 NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced net sales for the three months and full year ended December 31, 2025. Net Sales($ in millions)Three Months EndedYear EndedDecember 31,December 31,2025 2024 % Change2025 2024 % ChangeTotal Interparfums, Inc.$386 $362 7%$1,489 $1,452 2%European based net sale...
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.